# NORTH-REG Dwell-Time Study

> **NCT04701151** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Jørgen Bjerggaard Jensen** · enrollment: 314 (estimated)

## Conditions studied

- Side Effect of Drug

## Interventions

- **DRUG:** Bacillus Calmette Guerin

## Key facts

- **NCT ID:** NCT04701151
- **Lead sponsor:** Jørgen Bjerggaard Jensen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-03
- **Primary completion:** 2026-12
- **Final completion:** 2030-12
- **Target enrollment:** 314 (ESTIMATED)
- **Last updated:** 2026-03-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04701151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04701151, "NORTH-REG Dwell-Time Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04701151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*